DE60221283D1 - Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden - Google Patents
Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leidenInfo
- Publication number
- DE60221283D1 DE60221283D1 DE60221283T DE60221283T DE60221283D1 DE 60221283 D1 DE60221283 D1 DE 60221283D1 DE 60221283 T DE60221283 T DE 60221283T DE 60221283 T DE60221283 T DE 60221283T DE 60221283 D1 DE60221283 D1 DE 60221283D1
- Authority
- DE
- Germany
- Prior art keywords
- sup
- alzheimer
- disease
- dementia
- glycogensynthasekinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 102000001267 GSK3 Human genes 0.000 title abstract 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 title 1
- 150000005623 oxindoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34488501P | 2001-12-21 | 2001-12-21 | |
| US344885P | 2001-12-21 | ||
| PCT/SE2002/002371 WO2003055877A1 (en) | 2001-12-21 | 2002-12-18 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60221283D1 true DE60221283D1 (de) | 2007-08-30 |
| DE60221283T2 DE60221283T2 (de) | 2008-03-20 |
Family
ID=23352481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60221283T Expired - Lifetime DE60221283T2 (de) | 2001-12-21 | 2002-12-18 | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7342022B2 (de) |
| EP (1) | EP1458711B1 (de) |
| JP (2) | JP4393197B2 (de) |
| AT (1) | ATE367387T1 (de) |
| AU (1) | AU2002359162A1 (de) |
| DE (1) | DE60221283T2 (de) |
| ES (1) | ES2289171T3 (de) |
| WO (1) | WO2003055877A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| EP1846396A2 (de) * | 2005-02-11 | 2007-10-24 | Freie Universität Berlin | Substituierte 4-(indol-3-yl)chinazoline und ihre verwendung |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| MX2008010953A (es) * | 2006-02-28 | 2008-09-08 | Amgen Inc | Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10. |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2382975A3 (de) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US7851468B2 (en) | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN101573352A (zh) | 2006-10-21 | 2009-11-04 | 艾博特股份有限两合公司 | 杂环化合物和其作为糖原合酶激酶3抑制剂的用途 |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| CN102917700A (zh) * | 2010-03-26 | 2013-02-06 | 国立大学法人北海道大学 | 神经退行性疾病治疗药物 |
| MX336726B (es) | 2010-09-27 | 2016-01-27 | Abbott Gmbh & Co Kg | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3. |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| TW201639811A (zh) | 2015-03-13 | 2016-11-16 | 佛瑪治療公司 | 作為ＨＤＡＣ８抑制劑之α－桂皮醯胺化合物與組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| ES2289791T3 (es) * | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| CA2340701C (en) * | 1998-08-20 | 2009-05-26 | Sumitomo Pharmaceuticals Co., Ltd. | Oxindole derivatives as growth hormone releasers |
| EP1136493A1 (de) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
-
2002
- 2002-12-18 ES ES02793676T patent/ES2289171T3/es not_active Expired - Lifetime
- 2002-12-18 EP EP02793676A patent/EP1458711B1/de not_active Expired - Lifetime
- 2002-12-18 AT AT02793676T patent/ATE367387T1/de not_active IP Right Cessation
- 2002-12-18 AU AU2002359162A patent/AU2002359162A1/en not_active Abandoned
- 2002-12-18 JP JP2003556407A patent/JP4393197B2/ja not_active Expired - Fee Related
- 2002-12-18 WO PCT/SE2002/002371 patent/WO2003055877A1/en active IP Right Grant
- 2002-12-18 DE DE60221283T patent/DE60221283T2/de not_active Expired - Lifetime
- 2002-12-18 US US10/499,388 patent/US7342022B2/en not_active Expired - Fee Related
-
2009
- 2009-08-28 JP JP2009197766A patent/JP2010013459A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005516961A (ja) | 2005-06-09 |
| ES2289171T3 (es) | 2008-02-01 |
| WO2003055877A1 (en) | 2003-07-10 |
| JP2010013459A (ja) | 2010-01-21 |
| US7342022B2 (en) | 2008-03-11 |
| JP4393197B2 (ja) | 2010-01-06 |
| DE60221283T2 (de) | 2008-03-20 |
| EP1458711A1 (de) | 2004-09-22 |
| US20050222181A1 (en) | 2005-10-06 |
| EP1458711B1 (de) | 2007-07-18 |
| AU2002359162A1 (en) | 2003-07-15 |
| ATE367387T1 (de) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| DE60221283D1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| IL160028A (en) | Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| SE0104331D0 (sv) | Novel compounds | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| NO20023486L (no) | Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer | |
| ATE444069T1 (de) | Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| ATE288761T1 (de) | Verwendung von glykosaminoglykane zur behandlung seniler demenz | |
| HUP0301594A2 (hu) | E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére | |
| ATE451922T1 (de) | Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren | |
| ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| DE60231054D1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |